Latest News
Biogen Announces New Interim Phase 2 Results From NURTURE
Biogen recently announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA or nusinersen among pre-symptomatic infants with spinal muscular […]
Read More ›Cure SMA Launches Second Annual Community Survey to Address Important Issues in SMA Treatment
Dear Members of the SMA Community, For the past several years, we’ve been working to collect data and information on our community’s experiences, goals, hopes, and challenges. We know that […]
Read More ›Indiana is the Fourth State to Adopt Permanent SMA Screening
Last night, Governor Eric Holcomb of Indiana signed HB 1017, adding spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) to the state’s newborn screening panel. The bill makes Indiana […]
Read More ›Cure SMA Awards $150,000 Grant to Allison Ebert, PhD, Medical College of Wisconsin
Cure SMA has awarded a $150,000 research grant to Allison Ebert, PhD, at the Medical College of Wisconsin, for her project, “Role of astrocyte-produced miR-146a in SMA pathology.” SMA is […]
Read More ›Awareness is Best Raised When We Work Together
When a loved one is affected by spinal muscular atrophy, whether recently diagnosed or living with SMA for a while, you want to make a difference in their life and […]
Read More ›Cure SMA Welcomes New Medical Advisory Council Committee Members
We are excited to welcome 20 new members to our Medical Advisory Council (MAC). These clinicians represent eleven specialties, including specialties that were not previously represented on the MAC. Our […]
Read More ›